ESTRO 2023 - Abstract Book

S831

Monday 15 May 2023

ESTRO 2023

Materials and Methods 10 LAPC patients previously treated with CFRT were identified. For each patient, 2 SABR plans were generated for 35Gy in 5 fractions: an ITV and MidV plan. For MidV plans, the MidV phase (used for planning) was determined by contouring the GTV on all 10 4DCT phases and identifying the phase where the GTV centre of mass was closest to the average position. Individualised PTVMidV margins were calculated for each plane according to a modified Van Herk recipe(1,2)where motion was incorporated as a random error component. For ITV plans, the GTV was encompassed through its entire trajectory to form the ITV and a 3.1mm isometric PTVITV margin applied. PTVITV plans were produced on contrast enhanced CT. All error values within the PTVITV margin formula were the same as those used for PTVMidV margin calculations. IMRT plans were generated using Monaco(v5.40, Elekta, Stockholm). PTV coverage was optimised whilst respecting mandatory OAR constraints. OAR constraints were as per UK LAPC SABR guidelines(3). PTV volumes and PTV/OAR dosimetry were compared and assessed using Wilcoxon matched pairs test (significant p= ≤ 0.05). Results PTVMidV volumes were significantly smaller than PTVITV volumes (median 84.86cm ³ vs 108.07cm ³ , p=0.002). Dosimetric parameters are shown in Table 1. Larger PTVITVs resulted in more overlap with normal tissues, requiring greater compromise of PTV coverage to meet OAR constraints compared to MidV plans. For 1 patient, a clinically acceptable SABR plan was not achievable with the PTVITV approach, as adequate PTV coverage (V35Gy ≥ 60%, as per UK guidelines(3)) could not be achieved without exceeding mandatory OAR constraints. For this case, V35Gy:PTVITV = 54.9%, PTVMidV= 81%. The MidV approach always resulted in acceptable plans.

Conclusion Use of PTVMidV margins resulted in significantly smaller PTV volumes with less OAR overlap and a modest improvement in PTV coverage compared with PTVITV margins. A PTVMidV approach may help to produce clinically acceptable SABR plans (where not possible with PTVITV) and could facilitate dose escalation. We recommend PTVMidV margins for MRL SABR for LAPC and plan to use this approach in combination with abdominal compression. This will be reassessed when advanced motion management is available on the Elekta Unity MRL.

PD-0984 Are ultra-hypofractionated prostate treatments worse in some patients? - an in-silico study F. Claassen 1 , V. Coen 1 , I. Jacobs 1 , T. Harthoorn 1 , I. De Marco 1 , B. Mous-Van der Wegen 1 , F. Van den Heuvel 1 1 Zuidwest Radiotherapeutisch Instituut, Radiotherapy, Vlissingen, The Netherlands Purpose or Objective The current trend within radiotherapy is towards more hypo-fractionated (HF) treatments. In our institute, ultra hypofractionation (UHF) treatment for prostate patients is recently introduced into the clinic. In the initial treatment plan, dose at organs at risk is always minimized. However in practice, due to setup uncertainties and anatomical changes, the delivered dose at the organs at risk can be higher than initially planned. In UHF treatments, this effect can be more pronounced. This study investigates the radiobiological impact, on target and organs at risk, of random and systematic errors in ultra-hypofractionated (UHF) prostate treatments compared to hypo-fractioned (HF) prostate treatments.

Materials and Methods